Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial

Main Article Content

Benjamin Ehst
Oregon Medical Research Center, Portland, OR, USA

Richard B Warren
Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester, UK

H. Chih-ho Hong
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada

Dong Hun Lee
Department of Dermatology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

Andrei Metelitsa
Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Sebastian Volc
Department of Dermatology, University Hospital Tübingen, University of Tübingen, Tübingen, Germany

Marie Tauber
Department of Allergology and Immunology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France

Farzaneh Safavimanesh
LEO Pharma A/S, Ballerup, Denmark

Ann-Marie Tindberg
LEO Pharma A/S, Ballerup, Denmark

Linda Stein Gold
Henry Ford Health System, Detroit, MI, USA

Keywords

Tralokinumab, atopic dermatitis, Moderate-to-Severe Atopic Dermatitis, hand, ADHAND, clinical trial, treatment, hand involvement

Abstract

N/A

References

1. Lio PA, et al. J Drugs Dermatol. 2020;19(10):943-948.

2. Silverberg JI, et al. J Am Acad Dermatol. 2023;89(3):519-528.

3. Port LR, Brunner PM. Dermatol Clin. 2024;42(4):619-23.

4. Quaade AS, et al. Contact Dermat. 2021;84(6):361-374.

5. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05958407. Accessed January 2026.

Article Sidebar

PDF
Published
2026-03-10
DOI: https://doi.org/10.25251/ppt8ep84

Article Details

How to Cite
1.
Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-week Phase 3b ADHAND Trial. J of Skin. 2026;10(2):s744. doi:10.25251/ppt8ep84
Issue
Vol. 10 No. 2 (2026): March 2026 Issue
Section
Poster Presentations at 2026 Winter Clinical Dermatology Conference®: Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>